BiomX’s (PHGE) Buy Rating Reaffirmed at HC Wainwright

BiomX (NYSEMKT:PHGE)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $2.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 477.20% from the stock’s current price.

BiomX Stock Up 17.4 %

Shares of NYSEMKT:PHGE opened at $0.35 on Monday. The stock has a market capitalization of $19.13 million, a PE ratio of -0.65 and a beta of 1.36. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The firm’s 50-day moving average is $0.32 and its 200 day moving average is $0.31.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).